Physician profile
Michael G Uzmann
NPI 1265622260
$76,864.29
in general payments reported to CMS, 2019-2025
51 companies · $21K in 2025
The $21K reported for 2025 was more than what 93% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,850 · 2020: $2,658 · 2021: $5,366 · 2022: $22K · 2023: $12K · 2024: $11K · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $13K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,511 · Education: $32.27 · Travel and Lodging: $3.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24,161.44 |
| Food and Beverage | $12,973.91 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,511.00 |
| Education | $32.27 |
| Travel and Lodging | $3.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $43,892.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $8,286.25 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Insulet Corporation | $4,347.84 | 2019-2025 | Omnipod |
| Horizon Therapeutics Plc | $3,550.49 | 2020-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $2,240.98 | 2019-2024 | |
| Abbott Laboratories | $1,901.64 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Embecta Corp. | $1,131.44 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Tandem Diabetes Care, INC. | $1,081.24 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $1,024.31 | 2019-2022 | |
| Corcept Therapeutics | $1,020.81 | 2020-2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $941.50 | 2021-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $844.49 | 2020-2024 | Mounjaro |
| Medtronic, INC. | $735.40 | 2021-2024 | Minimed 780g |
| Abbvie INC. | $705.66 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $600.33 | 2021-2025 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Uzmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.